Invasive fungal infections are one of the major complications in pediatric patients during prolonged neutropenia after chemotherapy. Evaluation of the efficacy and safety of the triazole posaconazole in these patients is missing. This multicenter survey analyzed trough concentrations of 33 pediatric patients with a median age of 8 years during 108 neutropenic episodes who received prophylactic posaconazole oral suspension. A total of 172 posaconazole trough levels were determined to median 438 ng/ml (range 111-2011 ng/ml; mean 468 ± 244 ng/ml). Age and gender had no influence on posaconazole plasma levels. Posaconazole was not discontinued due to adverse events in any of the patients. Only hepatic parameters significantly increased beyond the upper normal limit to median values of ALT of 87 U/l (P < .0001), and AST of 67 U/l (P < .0001). One patient with a median posaconazole trough concentration of 306 ng/ml experienced an invasive fungal infection. In conclusion, posaconazole was effective, safe and feasible in 33 pediatric patients with neutropenia ≥5 days after chemotherapy. Median posaconazole plasma concentrations were approximately 1.6-fold lower than the recommended plasma level of 700 ng/ml. Larger patient cohorts are needed to evaluate these findings.
Introduction
Invasive fungal infections belong to the most severe infectious complications in pediatric patients with hematooncological malignancies and neutropenia. 1 The risk for invasive fungal infections in pediatric patients with acute leukemia is further increased with immunosuppression and during neutropenia. 2 The incidence of invasive fungal infections in these patients ranges from 7 to 21%. 1, 3 In particular, patients with neutropenia have a substantially increased risk for developing invasive fungal infections with Aspergillus and Candida spp. 4, 5 Rare invasive infections with Cryptococcus spp., Fusarium spp., or Zygomycetes are likewise life threatening complications in these patients. 3, 6 The correct diagnosis of invasive fungal infections is difficult and a timely start of antifungal therapy is critical for the patient outcome. A delay in therapy is associated with a strong increase in mortality. [7] [8] [9] To help prevent this problem, pediatric patients with an expected prolonged neutropenia receive antifungal prophylaxis. These mainly include patients with acute myeloid leukemia (AML) and recurrent acute leukemia. Antifungal prophylaxis with the extended-spectrum triazole posaconazole reduces the incidence of invasive fungal infections in adults with myelodysplastic syndromes (MDS) and AML. 7, [10] [11] [12] [13] Due to the favorable results on efficacy and low incidences of side effects of posaconazole in adults and excellent results at the presenting Children's Hospital in pediatric patients, the standard antifungal prophylaxis was changed from itraconazole and fluconazole to posaconazole. 7, [14] [15] [16] Data on efficacy and pharmacokinetics of posaconazole in pediatric patients are rare, but it is assumed that higher plasma concentrations correlate with better responses. [14] [15] [16] [17] [18] [19] The present survey analyzed the posaconazole plasma concentrations of pediatric patients with neutropenia (granulocytes <500 μl for ≥5 days) caused by chemotherapy or underlying disease. Further, efficacy, safety, and tolerability of prophylactic posaconazole were assessed in these patients.
Patients and methods
This analysis was conducted in accordance with the Declaration of Helsinki and performed with approval from the University Children's Hospital Tübingen's Institutional Review Board.
Study design
This multicenter retrospective survey performed at the University Children's Hospital Tübingen and the University Children's Hospital Dr. von Hauner'sches Kinderspital Munich analyzed the posaconazole serum concentrations in 33 pediatric patients under 18 years of age with hematooncological malignancies and nonmalignancies, who received antifungal monoprophylaxis with posaconazole suspension after chemotherapy from March 2010 to February 2016 and presented with minimum one period of neutropenia (neutrophil counts <500 μl for ≥5 days). Exclusion criteria were the occurrence of a proven, probable or possible invasive fungal infection before the start of antifungal prophylaxis, or a clinically relevant increase of transaminases, cholestasis, or kidney parameters.
All patients received a regular balanced diet provided by the hospital. Demographics, clinical factors, and survival were abstracted from clinical and research records of all patients and maintained on a prospective basis. The primary objective of this survey was to investigate the serum concentrations of posaconazole suspension and efficacy for prophylaxis for invasive fungal infections during neutropenia from chemotherapy or underlying disease in pediatric patients. The secondary objectives were to analyze the safety and feasibility of posaconazole suspension in pediatric patients with neutropenia.
The observation period was defined as the period from the day before start of posaconazole prophylaxis up to two weeks after the end of posaconazole prophylaxis. The treatment period was defined as the time during the observation period when antifungal monoprophylaxis with posaconazole was administered. Antifungal monoprophylaxis with posaconazole began 24 h after the end of chemotherapy cycle and ended minimum one day before start of the next chemotherapy cycle. After the last course of chemotherapy antifungal prophylaxis was terminated within 4 to 6 days after the end of neutropenia. Patients with severe aplastic anemia and granulocytopenia were given antifungal monoprophylaxis during the whole period of neutropenia until shortly before start of the planned conditioning regimen of hematopoietic stem cell transplantation (HSCT).
Administration of posaconazole and co-medication
All patients received posaconazole at a dosage of 4 mg kg/BW TID. The administration of posaconazole suspension was planned to occur approximately 10-15 minutes after a regular meal. All patients received supportive comedication with cotrimoxazole twice a week and omeprazole or ranitidine when necessary.
Posaconazole plasma concentrations
A minimum of three posaconazole trough levels per patient were analyzed. The time between each blood draw was at least 48 h. First blood sampling for determination of posaconazole concentration was minimum 7 days after the first posaconazole intake. For determination of posaconazole trough plasma concentrations excess material remaining after routine laboratory analyses was used. Posaconazole plasma concentrations were determined with high-performance liquid chromatography on a ReproSil-Pur Basic C 18 column (150 mm by 2 mm by 5 μm; Dr. Maisch GmbH, Ammerbuch, Germany) and a mobile phase consisting of 0.09 M aqueous ammonium phosphate monobasic (Riedel-de-Haën, Seelze, Germany) and acetonitrile (Merck, Darmstadt, Germany) (50%:50%, (v/v)). Posaconazole was detected at 260 nm with a UV-VIS diode array detector as described previously. 15 
Assessment of efficacy
During the observation period, the success of a posaconazole-based antifungal prophylaxis was defined as the absence of proven, probable and possible invasive fungal infections according to the EORTC/MSG criteria of 2008. 20 All patients included in this analysis were prospectively monitored for clinical signs of fungal infection, laboratory analyses and radiological workup when applicable. Galactomannan antigen was measured until the occurrence of fever with duration of 72 h ≥ 38.5
• C with a PLATELIA TM Aspergillus assay (Bio-Rad Laboratories, Munich, Germany) according to the manufacturer's instructions.
Assessment of safety and tolerance
Laboratory liver and kidney parameters and electrolytes were analyzed at baseline, defined as the day before start of the treatment period, during the treatment period, and at the end of the treatment period. The maximum (transaminases, total bilirubin, and direct bilirubin) and minimum (potassium, calcium, and phosphate) values during the treatment period were used for statistical analyses. The analysis of hepatic toxicity included transaminases alanine aminotransferase (ALT, normal range ≤39 U/l) and aspartate aminotransferase (AST, normal range ≤39 U/l), cholestasis parameters total bilirubin (normal range ≤1.1 mg/dl) and direct bilirubin (normal range ≤0.3 mg/dl). Serum creatinine (normal range ≤0.7 mg/dl) and urea (normal range ≤46 mg/dl) were analyzed to investigate renal function. In addition, an analysis of the electrolytes potassium (normal range ≥3.4 mmol/l), calcium (normal range ≥2.0 mmol/l), and phosphate (normal range ≥1.1 mmol/l) was performed. Clinically relevant increases of transaminases were defined as increases beyond the fivefold of the normal value 
Statistical analysis
Posaconazole plasma concentrations of all patients were analyzed in total and in groups of plasma levels between 100 and 300 ng/ml, between 301 and 500 ng/ml, between 501 and 700 ng/ml, and >700 ng/ml. Posaconazole plasma levels of all patients are displayed as boxplots and whiskers (min to max). Statistically significant differences of posaconazole plasma levels with respect of age and gender, comparison of patients with neutropenia ≥10 days versus patients with neutropenia <10 days or comparison of patients with and without diarrhea were tested by the Mann-Whitney U-test. The comparison between the posaconazole level during therapy with antacids with H 2 -receptor antagonist (ranitidine), and treatment with proton pump inhibitor (omeprazole) and the further comparison between the treatment with antacids and without antacids was conducted as well by the Mann-Whitney U-test. The Wilcoxon matchedpairs signed-ranks test was used for inferential statistical comparisons (baseline -maximum or minimum) of transaminases, cholestasis and kidney parameters, and electrolytes. The analysis of concentrations is presented as mean and standard deviation (SD) in the bar charts. To determine whether the sample group exhibited statistically significantly different values from the age-adjusted normal range, the one-sample t-test, or the Wilcoxon signed rank test were used. Statistically significant values were reported depending on the clinical relevance, that is, only if data were significantly higher or lower than the age-adjusted normal value (dotted line in bar charts).
P values of ≤ .05 ( * ), ≤ .01( * * ), and ≤ .001 ( * * * ) were defined as significant and symbolized in the figures. Graphs and statistical tests were created with GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla, CA, USA). 
Results
The present survey analyzed the posaconazole plasma concentrations of 19 male and 14 female patients with hematooncological malignancies and nonmalignancies, and with neutropenia of at least 5 days. The median age was 8 years (range 1.5-17.6 years). The patients received antifungal prophylaxis in a dose of 4 mg·kg/BW TID. Information on patient characteristics and chemotherapy regimen is presented in Table 1 and 2.
Treatment and observation period
The median observation period of all patients was 102 days (range 36-228 days). The antifungal treatment period, which included all days of antifungal prophylaxis with posaconazole, was at median 79 days (range 24-214 days). In total, antifungal prophylaxis with posaconazole was given during 108 neutropenic periods.
Neutropenia
The median duration of the 108 neutropenic episodes (neutrophil counts <500/μl) from chemotherapy for ALL, ALLrelapse, AML, AML-relapse, JMML, Ewing's sarcoma, neuroblastoma stage IV, and the two longer neutropenia periods of underlying disease in both patients with severe aplastic anemia or granulocytopenia was 8 days (range 5-214 days). 
Mortality
Out of 33 patients, one (3.0%) died during the observation period, due to relapse of the underlying disease. None of the patients included in the present analysis died from invasive fungal infection during the observation period. The pie chart of the same data shows trough concentrations between 100 and 300 ng/ml (32.2% of the values), between 301 and 500 ng/ml (34.4%), between 501 and 700 ng/ml (22.2%), and >700 ng/ml (11.1%).
Posaconazole plasma concentrations
The primary objective of this survey showed a total of 172 posaconazole serum trough levels that were measured from 33 patients during 108 periods of neutropenia ≥5 days. None of the patients received posaconazole with a higher fat nutrition or a liquid supplementation. A median of six trough levels (range 3-11) were measured per patient. Out of 172 trough levels, 42 (24.4%) measured between 100 and 300 ng/ml, 64 (37.2%) between 301 and 500 ng/ml, 46 (26.7%) between 501 and 700 ng/ml, and 20 (11.6%) were ≥700 ng/ml. The posaconazole concentration in the majority of samples and the average concentration per patient were above 300 ng/ml. The median posaconazole serum concentration of all 172 trough levels was 438 ng/ml; range 111-2011 ng/ml; mean 468 ± 244 ng/ml) (Fig. 1) . One of the 33 patients with a median posaconazole trough level of 306 ng/ml; range 141-635 ng/ml; mean 329 ± 143 ng/ml) was diagnosed with a proven fungal infection. These trough levels (n = 11) were significantly different (P = .018) from the posaconazole trough concentrations (n = 161) of the other 32 patients (median 452 ng/ml; range 111-2011 ng/ml; mean 479 ± 246 ng/ml) without invasive fungal infections. Out of 33 patients, 14 (42.4%) experienced neutropenic episodes ≥10 days. Their posaconazole plasma concentrations (n = 76; median 440 ng/ml; range 162-1770 ng/ml; mean 491 ± 229 ng/ml) was not significantly different (P = .1402) from the remaining 19 patients (57.6%) with neutropenic episodes <10 days (n = 96; median 437 ng/ml; range 111-2011 ng/ml; mean 453 ± 256 ng/ml).
Out of 33 patients, six (18.2%) developed diarrhea due to chemotherapy with a stool frequency of five defecations per day on at least five consecutive days. A comparison of the posaconazole trough levels of the group of patients with diarrhea (n = 34; median 397 ng/ml; Figure 2 . Posaconazole plasma concentrations in patients with and without diarrhea. The graph shows boxplots with whiskers (min to max) of posaconazole plasma concentrations of six of 33 patients (18.2%) with diarrhea and 27 of 33 (81.8%) patients without diarrhea. A comparison of the posaconazole trough levels of the group of patients with diarrhea (n = 34; mean 429 ± 171 ng/ml; median 397 ng/ml; range 162-763 ng/ml) with the levels of the patients without diarrhea (n = 138; mean 480 ± 259 ng/ml; median 451 ng/ml; range 111-2011 ng/ml) showed no statistically significant difference (P = .4128) (Mann-Whitney U-test).
range 162-763 ng/ml; mean 429 ± 171 ng/ml) with the levels of the patients without diarrhea (n = 138; median 451 ng/ml; range 111-2011 ng/ml; mean 480 ± 259 ng/ml) showed no statistically significant difference (P = .4128) (Fig. 2) .
Influence of age and gender
The mean posaconazole plasma concentration of patients under 12 years of age (n = 106) was 449 ± 237 ng/ml (median 406 ng/ml; range 120-2011 ng/ml) and thus not significantly different (P = .2944) from the mean posaconazole concentration of patients with an age of 12 to <17 years (n = 66; mean 505 ± 256 ng/ml, median 485 ng/ml; range 111-1770 ng/ml). The trough levels of all 19 male patients (n = 96; mean 456 ± 237 ng/ml; median 444 ng/ml; range 111-1770 ng/ml) were not significantly different (P = .42) from trough levels of the 14 female patients (n = 76; mean 480 ± 250 ng/ml, median 433 ng/ml; range 120-2011 ng/ml) (Fig. 2) .
Concomitant medication
Out of 33 patients, seven (21.2%; n = 35 plasma concentrations) received H 2 -receptor antagonist ranitidine, and four (12.1%; n = 28 plasma concentrations) were given the proton pump inhibitor omeprazole. The median posaconazole trough levels during treatment with ranitidine and omeprazole were 467 ng/ml (range 221-820 ng/ml; mean 506 ± 167 ng/ml) and 455 ng/ml (range 111-789 ng/ml; mean 442 ± 214 ng/ml), respectively. This difference was not statistically significant (P = .234). Likewise, a comparison of the posaconazole plasma concentrations of the 11 patients receiving the antacids omeprazole or ranitidine (n = 63 plasma levels; mean 477 ± 191 ng/ml; median 467 ng/ml; range 111-820 ng/ml) with the plasma levels of the other 22 patients who did not receive antacids (n = 109 plasma levels; mean 472 ± 273 ng/ml; median 423 ng/ml; range 141-2011 ng/ml) showed no statistically significant difference (P = .267).
Efficacy analysis
All 33 patients were included in the final efficacy analysis, which was the primary objective of the investigation. Out of 33 patients, one patient (3.0%) who was treated for granulocytopenia was diagnosed with a proven invasive fungal infection on day 104 after the start of antifungal prophylaxis with posaconazole. The patient experienced pain in the right lower abdomen and finally underwent appendectomy. The biopsy material showed evidence of an Aspergillus fumigatus infection. The analysis of Aspergillus galactomannan antigen in the blood was negative. As a result, treatment with posaconazole was increased from prophylactic dosage (4 mg In all other patients, no evidence of a proven, probable or possible invasive fungal infection was found according to the EORTC guidelines. 20 
Safety and tolerability analysis
The analysis for secondary objectives demonstrates the spectrum of adverse events, attributable to the antifungal monoprophylaxis with posaconazole that was characterized primarily by gastrointestinal symptoms such as abdominal pain in two patients and nausea in two other patients. Antifungal prophylaxis with posaconazole was not discontinued due to adverse events or clinically relevant increases of the analyzed blood parameters for any of the patients included in this analysis. A significant increase (P<.0001) of the ALT beyond the upper normal limit was observed during the observation period (mean 99.30 ± 64.62 U/l, median 87 U/l; range 13-290 U/l), in comparison to baseline values before start of posaconazole prophylaxis (mean 28.48 ± 13.82 U/l, median 26.0 U/l; range 6-56 U/l (Fig. 3A) . Likewise, AST was significantly increased (P<.0001) beyond the upper normal limit during the observation period, (mean 78.18 ± 57.15 U/l, median 67 U/l; range 17-289 U/l), in contrast to baseline values before start of posaconazole prophylaxis (mean 29.18 ± 15.92 U/l, median 28.0 U/l; range 9-82 U/l) (Fig. 3B) . Total bilirubin, direct bilirubin and the kidney parameters creatinine and urea did not significantly change during antifungal monoprophylaxis with posaconazole ( Fig. 3C-F) . The plasma values of the electrolytes potassium and calcium decreased during treatment with posaconazole but not significantly below the normal limit ( Fig. 3G-H) . A significant decrease (P < .0001) of phosphate values could be observed during the posaconazole administration (mean 1.0 ± 0.26 mmol/l; median 1.0 mmol/l; range 0.6-1.4 mmol/l), compared to baseline values (mean 1.5 ± 0.16 mmol/l; median 1.5 mmol/l; range 1.1-1.9 mmol/l) (Fig. 3I) .
Discussion
Posaconazole is an extended-spectrum triazole with efficacy against a broad range of serious fungal infections and superior efficacy and improved survival rates than fluconazole or itraconazole as antifungal prophylaxis in adult patients undergoing chemotherapy against MDS or AML. 7, 10 Up to date, only a few data are available on the prophylactic or therapeutic use of posaconazole and its pharmacokinetic properties in pediatric patients especially under the conditions of chemotherapy, HSCT and prolonged neutropenia. [14] [15] [16] [17] 19 Several studies on healthy volunteers and adult patients have shown that posaconazole resorption is highly variable between individuals and dependents on several factors such as gastric pH and motility, fat content of the nutrition, age, occurrence of diarrhea, and graft-versus-host disease or concomitant medication like acid-suppressing drugs. [22] [23] [24] [25] [26] The absolute bioavailability of posaconazole in adults ranges from 8 to 47% after oral ingestion and higher plasma levels of posaconazole are correlated with better clinical outcomes. 19, 27 Investigations on the structurally related fluconazole have shown a significantly higher clearance rate in pediatric patients than in adults making a relatively high dosage of fluconazole necessary to reach therapeutic serum levels in children. 28 Although the target posaconazole plasma concentration has not been exactly defined, yet the recommended posaconazole plasma concentration is ≥700 ng/ml. 29 It
is still unknown what posaconazole plasma concentration provides protection against invasive fungal infections.
In a prospective multicenter study, 304 adults with neutropenia from chemotherapeutic treatment of AML or MDS reached an average posaconazole plasma concentration of 583 ± 381 ng/ml. This was slightly higher than the concentrations obtained in the present analysis. Only seven of these 304 (2.3%) patients experienced invasive fungal infections. 7 A multicenter retrospective study reported on 72 adults with mainly hemato-oncological malignancies and posaconazole prophylaxis. In sum, 12 of 72 (16.7%) patients developed an invasive fungal infection. These patients had significantly (P < .01) lower median posaconazole plasma concentration (289 ng/ml) than the remaining 60 patients (83.3%) without invasive fungal infection (485 ng/ml). 18 Other studies have shown that posaconazole as salvage treatment improved the response rate in patients with invasive aspergillosis at a plasma concentration above 700 ng/ml. 30 In investigations on pediatric patients, it was evident that higher dosages of posaconazole lead to higher posaconazole plasma levels.
In a retrospective analysis of 33 pediatric patients (median age 11.5 years) who received posaconazole for treatment of invasive fungal infections with a median dosage of 20 mg·kg/BW/d in four divided doses, the posaconazole level was above 700 ng/ml in 63.6% of the cases. In sum, 12 of 33 (36.4%) patients, who received a median posaconazole dosage of 12.9 mg·kg/BW/d, had plasma concentrations below 700 ng/ml. 17 Similarly, median daily dosages of 16.5 mg·kg/BW in 12 pediatric patients lead to median plasma concentration of 579 ng/ml and were thus higher in comparison to the present analysis. 19 The primary objectives of the present survey were to analyze posaconazole plasma concentrations of pediatric patients at high risk during neutropenic periods for a minimum of 5 days. Out of 33 patients, one patient developed a proven invasive fungal infection with Aspergillus with a median posaconazole plasma concentration of 306 ng/ml. Interestingly, the patient's posaconazole level was significantly different (P = .018) from the overall median plasma concentration of the other 32 patients without an invasive fungal infection, who had a median posaconazole plasma concentration of 452 ng/ml. Of note, both the patient with the invasive fungal infection and the remaining 32 patients had average posaconazole serum concentrations substantially lower than the recommended level of 700 ng/ml.
Interestingly, median and mean posaconazole plasma trough concentrations of 27 pediatric patients after HSCT receiving the same dosage of posaconazole with regular nutrition (mean 1123 ± 811 ng/ml; median 1051 ng/ml; range 104-4616 ng/ml) in a previously performed study were 2.4-fold higher than the plasma concentrations of the reported cohort in this presented study (mean 468 ± 244 ng/ml; median 438 ng/ml; range 111-2011 ng/ml; P < .0001). 31 No proven, probable, or possible invasive fungal infection occurred in this patient group after HSCT. At this point, it remains unclear, why posaconazole plasma concentrations are significantly higher after HSCT than during neutropenia after chemotherapy. During neutropenia after high dose chemotherapy, posaconazole is given after a course of chemotherapy of approximately two to three weeks until the following course of chemotherapy. During this time, the patients' intestinal mucosa is very vulnerable and affected by the chemotherapy and might thus have an impaired resorption rate of posaconazole suspension. In comparison, patients after HSCT are started on posaconazole shortly before clinical discharge. At this point, the patients have no signs of aplasia or mucositis and thus might have a better intestinal resorption rate of posaconazole suspension resulting in the observed higher plasma levels. Similar observations have been described for plasma concentrations in adult patients. After oral administration of posaconazole suspension of 200 mg TID, mean plasma concentrations of 1280 ± 820 ng/ml after allogeneic HSCT were approximately 2.2-fold higher than during neutropenia after chemotherapy with 583 ± 381 ng/ml. 7, 32 The clinical side effects in this analysis occurred in 12.1% of the cases during the administration of posaconazole, which is rather low compared to observations made during the administration of other antifungal azoles in pediatric patients after HSCT or chemotherapy. The side effects observed here were limited to gastrointestinal complications and were similar to the side effects shown during treatment with posaconazole suspension. [14] [15] [16] The present survey analyzed 172 posaconazole plasma concentrations in 33 pediatric patients at high risk for fungal infections due to periods of neutropenia ≥5 days. The majority of samples (n = 130; 75.6%) and the average concentration per patient showed a posaconazole concentration above 300 ng/ml. In one patient, a proven fungal infection was observed. No probable and possible fungal infection occurred. Posaconazole did show good tolerability in this cohort of pediatric patients, with no discontinuation due to adverse events. Similar to adults, posaconazole plasma concentrations in children with neutropenia from chemotherapy have been significantly lower compared to levels in pediatric recipients of an allogeneic HSCT at the same center receiving the same dosage of posaconazole. Prospective clinical trials in pediatric patients with larger patient populations are needed to analyze posaconazole pharmacokinetics and to identify optimal dosage as well as potential drug interactions in this cohort in order to provide adequate and safe antifungal prophylaxis.
